CAR-T细胞输注时间与LBCL结局
国际多中心回顾性研究纳入1052例接受CD19 CAR-T治疗的复发/难治性大B细胞淋巴瘤成人患者,发现输注时间每延后1小时与进展、复发或死亡风险升高相关(HR 1.11,95%CI 1.03-1.20,P=.004);中午前输注者1年PFS为51.4%,中午及以后输注者为35.2%,总生存相似。
要点
- 每延后1小时输注,进展、复发或死亡风险增加(HR 1.11,95%CI 1.03-1.20,P=.004)。
- 中午前输注1年PFS 51.4%,中午及以后输注35.2%,总生存两组相似。
- 早输注PFS获益源于复发减少和完全缓解率提高。
核心结论
- CAR-T细胞输注时间可能影响治疗疗效,支持开展前瞻性昼夜节律指导的输注策略评估。
研究设计与样本
- 国际多中心回顾性研究,纳入7个中心2017-2025年接受CD19 CAR-T治疗的1052例复发/难治性大B细胞淋巴瘤成人患者。
主要发现
- 输注时间中位数为上午11:48(四分位距11:06至12:45)。
- 校正中心、产品和关键临床变量后,输注时间每延后1小时与进展、复发或死亡风险升高相关(HR 1.11,95%CI 1.03-1.20,P=.004)。
- 1年无进展生存率中午前输注组为51.4%,中午及以后输注组为35.2%,总生存两组相似。
- 早输注组的PFS获益由较低的复发率和较高的完全缓解率驱动。
- 免疫毒性无差异,但晚输注与更高的峰值炎症标志物和降低的第7天CAR-T细胞扩增相关。
临床怎么用
- 在缺乏前瞻性验证前,输注时间可作为可评估的节律因素,但不宜据此常规改变中午后输注安排。
局限性
- 研究为回顾性设计,输注时间与预后之间的因果关联需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Circadian rhythms orchestrate immune activation and effector function, yet whether within-day timing influences chimeric antigen receptor (CAR) T-cell therapy outcomes remains unknown. We conducted an international, multicenter retrospective study of 1052 adults with relapsed or refractory large B-cell lymphoma treated with CD19-directed CAR T-cell therapy across 7 centers (2017-2025). The median infusion time was 11:48 am (interquartile range, 11:06 am to 12:45 pm). Each hour later in infusion time was associated with an increased risk of progression, relapse, or death (hazard ratio, 1.11; 95% confidence interval, 1.03-1.20; P = .004) after adjustment for center, product, and key clinical variables. One-year progression-free survival (PFS) was 51.4% for early (before 12:00 noon) infusion vs 35.2% for late (at or after 12:00 noon) infusion, whereas overall survival was similar between groups. The PFS benefit was driven by lower relapse and higher complete response rates in the early infusion group. Although no differences were observed in immune toxicities, late infusion correlated with higher peak inflammatory markers and reduced day 7 CAR T-cell expansion. Together, these findings suggest that the timing of CAR T-cell infusion may influence therapeutic efficacy and support prospective evaluation of circadian-informed delivery strategies.
引用
- Luan D, Ben Valid O, Beyar-Katz O, et al. Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma. Blood. 2026. PMID: 41489404. doi:10.1182/blood.2025031476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。